The Elsevier journal publication characterizes PrecisionGel’s biomolecular release properties, adding peer-reviewed support for Vivos Inc.’s (USOTC:RDGL) clinical, regulatory and potential licensing efforts.
Key Investor Takeaways
- Vivos Inc. (USOTC:RDGL) has secured a peer-reviewed PrecisionGel publication covering three years of research into the polymer platform’s biomolecular release properties.
- The study provides additional scientific support for PrecisionGel, a patented carrier component used in both RadioGel and IsoPet.
- Vivos says the research could strengthen the technical foundation supporting its clinical programs at Mayo Clinic, Health Care Global Cancer Centre in India and other international centers.
- The publication may also improve PrecisionGel’s positioning as a universal drug delivery carrier, with pharmaceutical and industrial companies already testing the platform for their own applications.
- The expanded scientific record could support future regulatory submissions as Vivos targets markets including the UK, Australia, European Union, Japan and India.
Why RDGL Stock Is in Focus
The peer-reviewed PrecisionGel publication gives investors a new external scientific reference point for a technology that sits at the center of Vivos’ therapeutic platform.
Published in Elsevier’s Journal of Drug Delivery Science and Technology, the paper summarizes three years of development research conducted at Akina Inc., which developed and manufactures PrecisionGel for Vivos. The work examined how biomolecular release properties vary across different polymer concentrations and chemical compositions.
PrecisionGel is an injectable, temperature-sensitive thermogel. It remains liquid at room temperature to facilitate loading and injection before forming a gel at body temperature, allowing therapeutic agents to be immobilized at the target site.
That functionality underpins its role as the polymer carrier in RadioGel and IsoPet, while also providing the basis for Vivos to offer PrecisionGel independently for controlled local delivery applications.
Why This Matters for Investors
The immediate significance is scientific validation rather than a new regulatory approval or commercial agreement. For investors evaluating Vivos, the publication adds peer-reviewed evidence around one of the core components of its Precision Radionuclide Therapy platform.
That may be relevant as the company advances clinical programs involving RadioGel. Vivos says the publication provides scientific support for discussions with physicians, regulatory authorities and hospital ethics committees evaluating the technology.
There is also a separate potential commercial pathway. PrecisionGel is available to pharmaceutical and biomedical companies independently of RadioGel and IsoPet, and Vivos says a number of pharmaceutical and industrial corporations have been testing it for their own agent-release applications.
The peer-reviewed research could therefore strengthen PrecisionGel’s credibility in future licensing or co-development discussions. However, the announcement does not disclose any resulting licensing agreements, revenue or commercial terms, leaving the financial impact of this opportunity undetermined.
International expansion is another area to watch. Vivos believes the publication strengthens the scientific record available for future regulatory submissions in the UK, Australia, European Union, Japan and India.
What to Watch Next
Investors can now watch for whether the peer-reviewed PrecisionGel research translates into tangible progress across Vivos’ clinical, regulatory or commercial programs.
Key developments would include further advancement of RadioGel clinical programs, progress toward international regulatory submissions, and any licensing or co-development agreements arising from third-party testing of PrecisionGel. Updates on the company’s India manufacturing operation could also provide evidence of progress in its international expansion strategy.